Search Results
Feb 05, 2026, 08:04 ET TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced
More news about: TransCode Therapeutics, Inc.
Feb 05, 2026, 07:00 ET Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated
Feb 04, 2026, 09:00 ET Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Feb 04, 2026, 08:00 ET Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial
data analysis, tumor-specific targets will be identified for each child. Customized mRNA vaccines will then be manufactured in Australia by Southern RNA, with an expected turnaround of approximately 10 weeks from enrollment to dosing."Where Hope and Science Intersect"Providence's
More news about: Providence Therapeutics Holdings Inc
Feb 03, 2026, 09:00 ET 1,000 Dreams Fund and Colgate-Palmolive Announce 2025 Colgate-Palmolive Scholars
professionals.Ayushi P., Louisiana State University Health Sciences Center - New Orleans — Emerging healthcare scientist researching RNA-based therapies for cardiometabolic diseases affecting millions worldwide.Nowshin S., Spelman College — Future dentist focused
More news about: 1,000 Dreams Fund
Feb 02, 2026, 21:44 ET Avidity Biosciences Announces Expected Record Date for Spin-Off
Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced
More news about: Avidity Biosciences, Inc.
Feb 02, 2026, 16:00 ET CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform
Industry-leading non-human primate (NHP) data validates CREATE's differentiated receptor design, targeted RNA-LNP platform, and ability to repeat doseClinical entry planned H2 2026CAMBRIDGE, Mass., Feb.
More news about: CREATE Medicines, Inc.
Jan 30, 2026, 22:46 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO
RNA) related to its sale to Novartis AG. Under the terms of the proposed transaction, Avidity shareholders will receive $72.00 per share in cash.ACT
More news about: Monteverde & Associates PC
Jan 29, 2026, 17:31 ET Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight
Market AnalysisTesting for the hepatitis D virus remains limited despite its clinical importance. Lack of standardized HDV RNA assays hampers accurate detection of active infection and monitoring of treatment response. This contributes to underdiagnosis and delays in timely clinical
More news about: DelveInsight Business Research, LLP
Jan 29, 2026, 13:31 ET Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
of two genes simultaneously in one molecule for treatment of atherosclerotic cardiovascular disease due to mixed hyperlipidemia. The investigational RNA interference therapeutic targets both proprotein convertase subtilisin kexin 9 and apolipoprotein C3 genes, representing an important step forward enabled
More news about: USA News Group
Jan 29, 2026, 08:05 ET Skyhawk Therapeutics 公佈其用於治療 Huntington 疾病的藥物 SKY-0515 於第 1 期臨床試驗中 受試患者的九個月中期結果。
平台在為尚無核准疾病修飾療法的毀滅性疾病方面，提供首創的小分子藥物的強大能力。」Huntington 疾病是一種罕見、遺傳性、最終致命的神經退化性疾病，在美國有超過 40,000 名有症狀的患者，據估計全世界有數十萬人受到影響。 目前尚無核准的治療方法可以減緩或阻止疾病惡化。 SKY-0515 是一種口服的試驗性小分子 RNA 調節劑，由該公司的新型 RNA 調節平台 SKYSTAR® 開發而成。 SKY-0515 可在治療層面同時降低 HTT 蛋白和 PMS1 蛋白的水平。 PMS1 是體細胞 CAG 重複序列擴增和 HD 病理的另一個關鍵驅動因素，其作用有望與降低突變 HTT 所帶來的益處相輔相成。Skyhawk
More news about: Skyhawk Therapeutics
Jan 29, 2026, 07:48 ET A Skyhawk Therapeutics anuncia resultados provisórios de nove meses em pacientes de seu ensaio clínico de fase 1 do SKY-0515 como tratamento para a doença de Huntington
aprovados que retardem ou interrompam a progressão da doença. SKY-0515 é um modulador de RNA de molécula pequena em fase de pesquisa, administrado por via oral, desenvolvido por meio da nova plataforma de modulação de RNA da empresa, SKYSTAR®. O SKY-0515 reduz terapeuticamente ambas: proteína
More news about: Skyhawk Therapeutics
Jan 28, 2026, 19:35 ET UT Health San Antonio research shows Alzheimer's prevention potential in pairing cannabis ingredient, anti-inflammatory drug
including improved learning and memory performance, reduced beta-amyloid and tau pathology, and decreased markers of neuroinflammation.Single-cell RNA sequencing revealed that genes involved in synaptic function, inflammation and Alzheimer's disease risk were shifted back toward a healthier profile
More news about: UT Health San Antonio
Jan 28, 2026, 12:57 ET Skyhawk Therapeutics gibt Neun-Monats-Zwischenergebnisse bei Patienten aus der klinischen Phase-1-Studie mit SKY-0515 zur Behandlung der Huntington-Krankheit bekannt
Behandlungen, die das Fortschreiten der Krankheit verlangsamen oder aufhalten. SKY-0515 ist ein oral zu verabreichender, niedermolekularer RNA-Modulator, der im Rahmen der neuartigen RNA-Modulierungsplattform des Unternehmens, SKYSTAR®, entwickelt wurde. SKY-0515 reduziert therapeutisch das HTT-Protein
More news about: Skyhawk Therapeutics
Jan 28, 2026, 12:09 ET Skyhawk Therapeutics Umumkan Hasil Sementara Uji Klinis SKY-0515 Tahap 1 Selama Sembilan Bulan Pada Pasien Sebagai Pengobatan Penyakit Huntington
untuk memperlambat atau menghentikan perkembangan penyakit Huntington. SKY-0515 adalah modulator RNA molekul kecil yang diberikan secara oral dan bersifat eksperimen yang dikembangkan melalui platform modulasi RNA baru milik perusahaan, yakni SKYSTAR®. SKY-0515 secara terapeutik mengurangi
More news about: Skyhawk Therapeutics
Jan 28, 2026, 08:30 ET Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan
whole exome sequencing (WES) and whole transcriptome sequencing (WTS), the study enables a population-level analysis of resistance pathways across DNA, RNA and protein expression."In this large real-world analysis, clinical outcomes allowed Caris to pinpoint molecular features linked to treatment-specific
More news about: Caris Life Sciences
Jan 28, 2026, 08:00 ET Stellaromics Expands Pyxa™ 3D Spatial Transcriptomics Beta Program with Installation at Emory University School of Medicine
Dr. Hailing Shi to apply 3D spatial multi-omics to decode RNA regulation in the human brain and neurodegenerative diseases BOSTON, Jan. 28, 2026 /PRNewswire/ -- Stellaromics, a pioneer in high-resolution 3D
More news about: Stellaromics
Jan 28, 2026, 07:00 ET Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe,
More news about: Insmed Incorporated
Jan 28, 2026, 03:11 ET Společnost Skyhawk Therapeutics oznamuje průběžné výsledky za devět měsíců u pacientů z 1. fáze klinického hodnocení přípravku SKY-0515 pro léčbu Huntingtonovy choroby
zpomalovala nebo zastavovala progresi onemocnění. SKY-0515 je perorálně podávaný modulátor RNA s malými molekulami, který byl vyvinut na základě nové platformy společnosti SKYSTAR® pro modulaci RNA. SKY-0515 v rámci léčby snižuje hladinu proteinu HTT i proteinu PMS1. PMS1 je dalším
More news about: Skyhawk Therapeutics
Jan 27, 2026, 22:10 ET Spoločnosť Skyhawk Therapeutics oznamuje predbežné výsledky u pacientov z fázy 1 klinického skúšania lieku SKY-0515 za deväť mesiacov liečby Huntingtonovej choroby
postupy, ktoré by spomalili alebo zastavili progresiu ochorenia. Liek SKY-0515 je perorálne podávaný, experimentálny nízkomolekulárny RNA modulátor vyvinutý prostredníctvom novej RNA-modulačnej platformy spoločnosti SKYSTAR®. Liek SKY-0515 terapeuticky redukuje proteín HTT ako aj proteín PMS1. Proteín
More news about: Skyhawk Therapeutics
Jan 27, 2026, 14:05 ET Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
Stoke is dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen as a first-in-class potential disease-modifying treatment
More news about: Anchor Line Partners
Jan 27, 2026, 10:22 ET Skyhawk Therapeutics Công Bố Kết Quả Nghiên Cứu Tạm Thời trên Bệnh Nhân sau 9 Tháng tiến hành Thử Nghiệm Lâm Sàng Giai Đoạn 1 thuốc SKY-0515 để Điều Trị bệnh Huntington
tiến triển của bệnh. SKY-0515 là một loại thuốc phân tử nhỏ dùng đường uống, có khả năng điều chỉnh RNA. Đây là sản phẩm đang trong giai đoạn nghiên cứu, được phát triển thông qua nền tảng điều biến RNA mới của công ty - SKYSTAR®. SKY-0515 có tác dụng điều trị giúp làm giảm cả protein HTT và
More news about: Skyhawk Therapeutics
Jan 27, 2026, 09:40 ET Skyhawk Therapeutics ogłasza dziewięciomiesięczne wyniki pośrednie badań klinicznych fazy 1 nad lekiem SKY-0515 stosowanym w leczeniu choroby Huntingtona
metod leczenia, które spowalniałyby lub zatrzymywały postęp choroby. SKY-0515 to doustny, badany modulator RNA o małej masie cząsteczkowej, opracowany w oparciu o nowatorską platformę modulującą RNA firmy SKYSTAR®. SKY-0515 terapeutycznie redukuje zarówno białko HTT, jak i białko PMS1. PMS1 jest dodatkowym
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:47 ET nRichDX and Hamilton Advance Automated Liquid Biopsy Sample Prep Solution with Unprecedented Capability
BiopsyThe integrated solution delivers an automated, end-to-end workflow for isolating circulating cell-free DNA (cfDNA), circulating cell-free RNA (cfRNA), circulating cell-free total nucleic acid (cfTNA), and circulating tumor cells (CTCs) from plasma, urine, and other biofluids with minimal hands-on
More news about: nRichDX and Hamilton
Jan 27, 2026, 08:00 ET 스카이호크 테라퓨틱스, 헌팅턴병 치료제 SKY-0515 제1상 임상시험 환자 대상 9개월 중간 결과 발표
초래하는 신경퇴행성 질환으로, 미국 내 4만 명 이상의 증상 발현 환자가 있으며 전 세계적으로 수십만 명이 이를 앓고 있는 것으로 추정된다. 현재 질병의 진행을 늦추거나 멈추는 승인된 치료제는 없다. SKY-0515는 회사의 혁신적인 RNA 조절 플랫폼인 SKYSTAR®를 통해 개발된 경구용 조사용 저분자 RNA 조절제다. SKY-0515는 HTT 단백질과 PMS1 단백질을 모두 치료적으로 감소시킨다. PMS1은 체세포 CAG 반복 확장 및 헌팅턴병 병리학의 또 다른 핵심 동인으로, 변이 HTT 감소의 이점을 보완할 것으로 기대된다.스카이호크는
More news about: Skyhawk Therapeutics